Dr. Noon CVD
A retinal-based AI diagnostic solution that autonomously assesses the future risk of cardiovascular disease (CVD).
Check your cardiovascular disease risk with retina image
*DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories
Features
The first retinal-based AI solution to assess your cardiovascular risk
Dr. Noon expands solutions to detect heart disease. You can predict your personalized CVD risk without a blood sampling or radiation
Effective CVD risk stratification and triage tool
Our deep-learning algorithm can estimate your Cardiovascular Disease risk as an adjunct to the formal risk assessment tools such as heart CT scan
Meeting prognostic performance of heart CT in projecting CVD events
Dr. Noon CVD can autonomously predict your future CVD risk while meeting the heart CT performance
Meet Dr. Noon CVD
*DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories
Dr. Noon CVD vs. Heart CT scan for Risk Stratification
When compared with the coronary artery calcium score from the traditional heart CT scan, Dr. Noon CVD successfully stratifies the cumulative cardiovascular disease events risk into three groups(low, moderate, high) and shows similar stratification patterns as heart CT scan
Cardiovascular Disease Events in 5 Years
Dr. Noon CVD
Retina-based Coronary Artery Calcium score
Heart CT scan
Heart CT-based Coronary Artery Calcium Score
Kaplan-Meier estimates for cumulative incidence of cardiovascular events in the CMERC-HI cohort (A) Cardiovascular disease event by RetiCAC score. (B) Cardiovascular disease event by CAC score. Cumulative event rates of cardiovascular disease events including incident heart failure, stroke, myocardial infarction, and all-cause mortality using the new three-strata risk stratification system of deep learning-based RetiCAC score (A), and CAC stratification (0, >0–100, and >100) (B) in the clinical cohort of CMERC-HI (n=527). CMERC-HI=Cardiovascular and Metabolic Disease Etiology Research Center-High Risk. CAC=coronary artery calcium. RetiCAC=deep-learning retinal coronary artery calcium.
Benefits
Safe
Skip any blood tests or radiation exposure while meeting the CT performance
Affordable
Save costs through early detection of stroke and heart disease prevention
Accessible
Provide patients with comprehensive cardiovascular risk management in a primary care setting
Dr. Noon CVD vs. current measurement
Dr. Noon CVD
Measured by Retina-based Coronary Artery Calcium Score
- No radiation risk or blood test
- Similar to retina photo cost
- Available in primary care setting
- From test to result within a minute
- Comparable performance to heart CT scan in risk assessment
Heart CT Scan
Measured by Heart CT-based Coronary Artery Calcium Score
- Exposure to high-dose radiation
- Not available in primary care settings
- Relatively high cost
- Test is taken by operation staff, read by radiologists, and delivered to patients by cardiologists, taking few weeks from test to result
Carotid Ultrasound
Measured by Carotid Intima-Media Thickness
- Test can be taken only by physicians for over 10 minutes
- Relatively low accuracy compared to coronary artery calcium score in predicting cardiovascular disease risk
- Higher cost than taking a retina photo
How Dr. Noon CVD works
Eye Scan
Take 1 retinal photograph per eye using a fundus camera by optometrists or technicians
Upload
Submit images to the cloud for analysis and type patient information
Analysis
Automatically analyze for signs of CVD risk within a minute
Report
Generate personalized health screening results and download the report
Referral
Refer to specialists for further follow-up or suggest lifestyle changes and regular check-ups
Get your result immediately.
Approval of Medical device & Commercial use
Approved in 8 territories, Reimbursed in Korea
Mediwhale is the only company that obtained approval for cardiovascular disease risk assessment using retinal images as a biomarker. Dr. Noon CVD has approvals for medical devices in the EU and Asia and is under FDA clearance in the US.
Dr. Noon CVD has been selected for the Postponement of New Health Technology Assessment (nHTA) in Korea. It has become the pioneering medical AI technology that physicians can use for early detection of CVD. Patients now have a formal process to get reimbursement for Dr. Noon CVD.
DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories.
Publication
Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs
The Lancet Digital Health
Coronary Artery Calcium (CAC) score is a clinically validated marker of cardiovascular disease risk.
Publication
Pivotal trial of a deep-learning-based retinal biomarker (Reti-CVD) in the prediction of cardiovascular disease: data from CMERC-HI
JAMIA